IFNGR1 and melanoma: Even if, IFN-γ alone has been tested in clinical trials in melanoma and failed (130, 131), patients harboring DNA lesions in gene encoding for IFN-γ, as well as mice carrying tumors mutated in IFNGR1, poorly responded to immunotherapy.